Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05275998 · ClinicalTrials.gov registry record · Phase 1
TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals
A Phase 1 study, sponsored by TaiMed Biologics.
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT05275998 is a Phase 1 study that has completed, run by TaiMed Biologics. The registered enrollment target is 51 participants.
The verdict
NCT05275998, a Phase 1 study, has completed, sponsored by TaiMed Biologics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
TMB-365 is a monoclonal antibody that binds to the CD4 receptor. TMB-380, aka VRC-07-523LS is a monoclonal antibody that binds to HIV. Both interfere with HIV entry. This study is designed to test various doses of the combination of the antibodies for safety and pharmacokinetics in suppressed subjects on cART. Once dosing is established based on safety and PK, the optimally dosed combinations will be assessed as maintenance therapy in HIV infected suppressed individuals discontinuing oral cART for 24 weeks.
Interventions
- DRUG TMB-365/TMB-380
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2022-07-05 |
| Est. Completion | 2024-11-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05275998
The ClinicalTrials.gov registry entry for NCT05275998 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TaiMed Biologics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TMB-365/TMB-380 is the first listed.
NCT05275998 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05275998 about?
NCT05275998 is a clinical study titled "TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals". TMB-365 is a monoclonal antibody that binds to the CD4 receptor. TMB-380, aka VRC-07-523LS is a monoclonal antibody that binds to HIV. Both interfere with HIV entry. This study is designed to test various doses of the combination of the antibodies for safety and pharmacokinetics in suppressed subjec...
What is the current status of trial NCT05275998?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2022-07-05. Estimated completion is 2024-11-20.
What interventions are being tested in trial NCT05275998?
The interventions under investigation include: TMB-365/TMB-380 (DRUG).
Who is sponsoring clinical trial NCT05275998?
This trial is sponsored by TaiMed Biologics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.